Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (16,901,876)	$ (11,953,881)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	487,116	568,380
Accretion of discount on NuvoGen obligation	(8,657)	(9,206)
Provision for excess inventory	184,540	60,143
Amortization of SVB Term Loan discount and issuance costs	328,850	351,068
Stock-based compensation expense	637,121	1,000,368
Employee stock purchase plan expense	36,765	41,950
Non-cash operating lease expense	305,362	359,014
Accrued interest on available-for-sale securities investments	(17,363)	(18,394)
Gain on forgiveness of PPP Loan		(1,735,792)
(Gain) loss on abandonment and disposal of assets, net	(104,000)	178,925
Changes in operating assets and liabilities:
Accounts receivable	1,132,052	(597,489)
Inventory	(183,536)	(892,655)
Prepaid expenses and other	(386,353)	(300,469)
Accounts payable	(937,550)	(50,230)
Accrued liabilities	(629,072)	205,015
Contract liabilities	(20,652)	53,062
Operating lease liabilities	(307,342)	(378,355)
Net cash used in operating activities	(16,384,595)	(13,118,546)
Investing activities
Purchase of property and equipment	(23,043)	(590,736)
Proceeds from the sale of property and equipment	104,000
Maturities of available-for-sale securities	16,650,000	9,000,000
Purchase of available-for-sale securities	(7,610,724)	(17,871,203)
Net cash (used in) provided by investing activities	9,120,233	(9,461,939)
Financing activities
Proceeds from ATM Offering, net of commissions of $0.3 million		10,665,819
Proceeds from March 2022 Purchase Agreement, net of $0.5 million of issuance costs	7,034,049
Proceeds from LP Purchase Agreement		599,979
Payments on NuvoGen obligation	(372,624)	(379,431)
Payments on SVB Term Loan	(5,955,882)
Payments on SVB Term Loan Amendment issuance costs	(14,282)
Payments on deferred offering costs	(80,692)
Payments on financing leases	(13,033)	(18,040)
Proceeds from exercise of stock options		326
Taxes paid for net share settlement of restricted stock awards	(10,792)	(2,571)
Proceeds from shares purchased under stock purchase plans	23,327	53,437
Proceeds from exercise of pre-funded warrants	2,411
Proceeds from insurance note	822,889
Payments on insurance notes	(530,790)	(494,352)
Net cash provided by financing activities	904,581	10,425,167
Effect of exchange rates on cash	(27,718)	(12,848)
Decrease in cash and cash equivalents	(6,387,499)	(12,168,166)
Cash and cash equivalents at beginning of period	9,599,950	22,397,812
Cash and cash equivalents at end of period	3,212,451	10,229,646
Supplemental disclosure of noncash investing and financing activities
Issuance of common stock upon conversion of Series A convertible preferred stock	1,402,430
Issuance of common stock from cashless exercise of pre-funded warrants		145
2021 Insurance Note issued for insurance premiums		746,360
Gain on forgiveness of PPP Loan		1,735,792
Operating lease right-of-use assets obtained in exchange for operating lease liabilities		1,302,457
Carrying value of demonstration units transferred from property and equipment to inventory		16,128
Supplemental cash flow information
Cash paid for interest	389,911	450,344
Cash paid for taxes	$ 7,131	$ 12,665